Home > Cardiology > No benefit of percutaneous reduction of secondary mitral regurgitation in HF patients over standard care

No benefit of percutaneous reduction of secondary mitral regurgitation in HF patients over standard care

Expert
Prof. Jean-Francois Obadia, Civil Hospices of Lyon, France
Conference
ESC 2019
Trial
MITRA-FR
Two-year results of the MITRA-FR trial confirm that the addition of percutaneous clip to medical treatment did not decrease the rate of death or unplanned hospitalisation for heart failure (HF). Although researchers noted that they observed trends in subgroup or post-hoc analysis, the lack of power limits the relevance of such analysis. Therefore, longer follow-up is needed as well as a meta-analysis on individual data. Until recently, the evidence on the efficacy of percutaneous correction of secondary mitral regurgitation in HF patients, mainly based on two studies, was conflicting [1,2]. As longer duration of one of the trials may be an influencing factor, a 2-year follow-up of patients in MITRA-FR was set up. Primary objective of the study was efficacy and safety of percutaneous mitral valve repair in patients with HF and severe secondary mitral regurgitation. Primary endpoint of the study was the composite of all-cause death or first unplanned rehospi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on